Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

CLL

Feature Video
Kristie L. Kahl
Single agent Copiktra (duvelisib) induced robust, durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with Arzerra (ofatumumab).
Kristie L. Kahl
Frontline use of Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) significantly reduced the risk for disease progression or death among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), especially in those with high-risk disease.
Kristie L. Kahl
This week, we spoke with former NFL coach, motivational speaker and acute promyelocytic leukemia survivor Chuck Pagano about his journey with cancer, and what has inspired him to give back following his diagnosis.
Jessica Skarzynski
In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), high doses of curcumin and vitamin D could help stabilize the disease, according to new research presented at the American Society of Hematology’s (ASH) Annual Meeting in San Diego.
Brielle Benyon
Administering Imbruvica with CAR-T cell therapy improved outcomes in patients with chronic lymphocytic leukemia, according to recent research.
Brielle Benyon
Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed.
Beth Fand Incollingo
An oncologist and three advocates were honored for their work on behalf of people with chronic lymphocytic leukemia.
Brielle Benyon
While CAR-T cell therapy has potential in treating CLL, T-cell fatigue and toxicity still raise many concerns.
Brielle Benyon
CLL is the most common type of leukemia in adults across the United State. Here's what you need to know about the disease.
Beth Fand Incollingo
What’s the best plan for lowering cancer drug prices? A panel of experts debated the possibilities.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other